Rafael F. Duarte
A5076623303- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Chronic Myeloid Leukemia Treatments
- Antifungal resistance and susceptibility
- Neutropenia and Cancer Infections
- COVID-19 Clinical Research Studies
- Chronic Lymphocytic Leukemia Research
- CAR-T cell therapy research
- Multiple Myeloma Research and Treatments
- Cytomegalovirus and herpesvirus research
- Fungal Infections and Studies
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Immune Cell Function and Interaction
- Childhood Cancer Survivors' Quality of Life
- Renal Transplantation Outcomes and Treatments
- Polyomavirus and related diseases
- T-cell and B-cell Immunology
- COVID-19 and healthcare impacts
- Mesenchymal stem cell research
- Lymphoma Diagnosis and Treatment
- Cutaneous lymphoproliferative disorders research
- Pneumocystis jirovecii pneumonia detection and treatment
- SARS-CoV-2 and COVID-19 Research
- Hemoglobinopathies and Related Disorders
Hospital Universitario Puerta de Hierro Majadahonda
2016-2025
Institute for Social Security and Services for State Workers
2024-2025
Universidade Federal da Bahia
2025
Universidad Autónoma de Zacatecas "Francisco García Salinas"
2024
Universidad Autónoma de Madrid
2017-2024
Centro de Investigación en Red en Enfermedades Cardiovasculares
2023
Universidade Federal de Pelotas
2023
King's College London
2005-2022
Institut Català d'Oncologia
2010-2021
Duran i Reynals Hospital
2012-2021
The 2005 National Institutes of Health (NIH) Consensus Conference proposed new criteria for diagnosing and scoring the severity chronic graft-versus-host disease (GVHD). 2014 NIH consensus maintains framework prior with further refinement based on evidence. Revisions have been made to address areas controversy or confusion, such as overlap GVHD subcategory distinction between active past tissue damage. Diagnostic involvement mouth, eyes, genitalia, lungs revised. Categories should be defined...
Cytomegalovirus (CMV) infection remains a common complication after allogeneic hematopoietic-cell transplantation. Letermovir is an antiviral drug that inhibits the CMV-terminase complex.In this phase 3, double-blind trial, we randomly assigned CMV-seropositive transplant recipients, 18 years of age or older, in 2:1 ratio to receive letermovir placebo, administered orally intravenously, through week 14 transplantation; randomization was stratified according trial site and CMV disease risk....
Chronic graft-versus-host disease (GVHD) is the leading cause of later illness and death after allogeneic hematopoietic stem-cell transplantation. We hypothesized that inclusion antihuman T-lymphocyte immune globulin (ATG) in a myeloablative conditioning regimen for patients with acute leukemia would result significant reduction chronic GVHD 2 years peripheral-blood transplantation from an HLA-identical sibling.We conducted prospective, multicenter, open-label, randomized phase 3 study ATG...
Sinusoidal obstruction syndrome, also known as veno-occlusive disease (SOS/VOD), is a potentially life threatening complication that can develop after hematopoietic cell transplantation. Although SOS/VOD progressively resolves within few weeks in most patients, the severe forms result multi-organ dysfunction and are associated with high mortality rate (>80%). Therefore, careful attention must be paid to allow an early detection of SOS/VOD, particularly drugs have now proven effective...
A record number of 40 829 hematopoietic stem cell transplantation (HSCT) in 36 469 patients (15 765 allogeneic (43%), 20 704 autologous (57%)) were reported by 656 centers 47 countries to the 2014 survey. Trends include: continued growth transplant activity, more so Eastern European than west; a increase use haploidentical family donors (by 25%) and slower for unrelated donor HSCT. The cord blood as source has decreased again 2014. Main indications HSCT leukemias: 11 853 (33%; 96%...
Several international recommendations address the assessment of graft-versus-host disease (GvHD) after hematopoietic cell transplantation (HCT). This position statement by GvHD experts from European Society for Blood and Marrow Transplantation (EBMT), National Institutes Health (NIH) Center International Transplant Research (CIBMTR) reviews existing guidelines both acute chronic GvHD, addresses potential confusions that arise in daily practice proposes consensus definitions many key terms....
Numbers of Hematopoietic cell transplantation (HCT) in Europe and collaborating countries continues to rise with 48,512 HCT 43,581 patients, comprising 19,798 (41%) allogeneic 28,714 (59%) autologous, reported by 700 centers 51 during 2019. Main indications were myeloid malignancies 10,764 (25%), lymphoid 27,895 (64%), nonmalignant disorders 3173 (7%). A marked growth CAR-T cellular therapies from 151 2017 1134 patients 2019 is observed. This year's analyses focus on changes over 30 years....
Chimeric antigen receptor (CAR) T cells are a novel class of anti-cancer therapy in which autologous or allogeneic engineered to express CAR targeting membrane antigen. In Europe, tisagenlecleucel (Kymriah™) is approved for the treatment refractory/relapsed acute lymphoblastic leukemia children and young adults as well relapsed/refractory diffuse large B-cell lymphoma, while axicabtagene ciloleucel (Yescarta™) high-grade lymphoma primary mediastinal lymphoma. Both agents genetically CD19....
Information on incidence, and factors associated with mortality is a prerequisite to improve outcome after hematopoietic stem cell transplantation (HSCT). Therefore, 55′668 deaths in 114′491 patients HSCT (83.7% allogeneic) for leukemia were investigated landmark analysis causes of death at day 30 (very early), 100 (early), 1 year (intermediate) 5 years (late). Mortality from all decreased cohort (1980–2001) 2 (2002–2015) post-transplant phases autologous HSCT. After allogeneic HSCT,...
Patients with hematological malignancies (HM) are at high risk of mortality from SARS-CoV-2 disease 2019 (COVID-19). A better understanding factors for adverse outcomes may improve clinical management in these patients. We therefore studied baseline characteristics HM patients developing COVID-19 and analyzed predictors mortality. The survey was supported by the Scientific Working Group Infection Hematology European Association (EHA). Eligible analysis were adult laboratory-confirmed...
For over two decades, the EBMT has updated recommendations on indications for haematopoietic cell transplantation (HCT) practice based clinical and scientific developments in field. This is eighth special report HCT haematological diseases, solid tumours immune disorders. Our aim to provide general guidance according prevailing countries centres. In order inform patient decisions, these must be considered conjunction with risk of disease, procedure non-transplant strategies, including...
Abstract Background Patients with cancer have been shown to a higher risk of clinical severity and mortality compared non-cancer patients COVID-19. hematologic malignancies typically are known levels immunosuppression may develop more severe respiratory viral infections than solid tumors. Data on COVID-19 in limited. Here we characterize disease evaluate potential prognostic factors for mortality. Methods In this population-based registry study, collected de-identified data characteristics,...
Low pretest risk of invasive aspergillosis renders serum galactomannan screening unreliable in asymptomatic patients undergoing effective prophylaxis (test results always negative or false positive). However, it remains useful for diagnosis with a clinical suspicion fungal disease. Background. There is practical need to investigate the performance (GM) assay hematology potentially low following antimold prophylaxis. Methods. We present 4-year study 262 unselected consecutive high-risk...
A record number of 39 209 HSCT in 34 809 patients (14 950 allogeneic (43%) and 19 859 autologous (57%)) were reported by 658 centers 48 countries to the 2013 survey. Trends include: more growth than HSCT, increasing use sibling unrelated donors a pronounced increase haploidentical family when compared with cord blood for those without matched related or donor. Main indications leukemias, 11 190 (32%; 96% allogeneic); lymphoid neoplasias, 958 (57%; 11% solid tumors, 1543 (4%; 4% nonmalignant...